Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) announced that Stacey Tinianov, MPH, a member of Jaguar's Scientific Advisory Board, will present a poster at the American Society of Clinical Oncology (ASCO) Quality Care Symposium on September 27, 2024. The presentation, titled 'Measuring what really matters: Advocacy-led co-creation and accrual of a pan-cancer QoL survey,' will discuss the methodologies used in designing the 'More Than a Diagnosis' quality of life survey for cancer patients and survivors.
The survey, sponsored by Jaguar's family company Napo Pharmaceuticals, aims to address the limitations of commonly used tools in assessing cancer patients' quality of life concerns. Tinianov emphasized that while cancer treatments have advanced, significant side effects can still impact patients' quality of life. The presentation will highlight the importance of understanding patients' priorities to improve supportive care and effectively address quality of life impacts.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, JAGX gained 5.91%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Jaguar's commercial focus on cancer supportive care aims to use the best tools and techniques that assess the quality of life of cancer patients and survivors and deliver solutions to address these unmet needs - Commonly used tools and techniques fail to measure what patients are most concerned about
Jaguar family company Napo Pharmaceuticals sponsored the "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer"
SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Stacey Tinianov, MPH, the founder of Advocates for Collaborative Education (ACE) and a member of Jaguar's Scientific Advisory Board, will conduct a poster presentation on September 27, 2024 at the American Society of Clinical Oncology (ASCO) Quality Care Symposium. The presentation, titled "Measuring what really matters: Advocacy-led co-creation and accrual of a pan-cancer QoL survey," will describe the methodologies and best practices used to design and execute "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer." The "More Than a Diagnosis" survey, an online, anonymous ACE survey initiative to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, was sponsored by Jaguar family company Napo Pharmaceuticals and presented by Tinianov and other members of ACE at the December 2023 San Antonio Breast Cancer Symposium. The abstract for the September 27, 2024 presentation can be viewed by clicking here.
"While cancer treatments have advanced considerably since the advent and availability of targeted therapies, significant short- and long-term treatment side effects can be challenging or even devastating to an individual's quality of life (QoL). Unfortunately the tools and techniques commonly used to assess the QoL of cancer patients and survivors often fail to measure what patients and survivors are most concerned about," said Tinianov. "Management of treatment side effects is integral to supportive care, and understanding what matters most to individuals can potentially guide improvements in supportive care to effectively address QoL impacts. I am delighted about the opportunity to share the co-creation methodologies that made that survey successful at the ASCO Quality Care Symposium."
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Tinianov will conduct a poster presentation September 27, 2024 at the ASCO Quality Care Symposium. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What is the focus of Jaguar Health's presentation at the ASCO Quality Care Symposium on September 27, 2024?
Who is presenting the poster at the ASCO Quality Care Symposium for Jaguar Health (JAGX)?
What is the main goal of the 'More Than a Diagnosis' survey sponsored by Jaguar Health's (JAGX) family company?
How does Jaguar Health (JAGX) plan to use the insights from the quality of life survey?
